Douglas Tremblay1, Vaibhav Patel1, Kenneth M Fifer1, Jessica Caro1, Olivia Kolodka2, John Mandelli3, Charles L Shapiro4. 1. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2. Dubin Breast Center, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, PO Box 1079, New York, NY, 10029, USA. 3. Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mt Sinai, New York, NY, USA. 4. Dubin Breast Center, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, PO Box 1079, New York, NY, 10029, USA. Charles.Shapiro@mssm.edu.
Abstract
INTRODUCTION: Aromatase inhibitors (AIs) are the preferred therapy for postmenopausal women with early-stage estrogen receptor-positive breast cancers. However, their use causes bone loss and increased risks of osteoporosis and fractures. METHODS: This is a retrospective review of all postmenopausal women with breast cancer diagnosed and treated with AI between 2010 and 2015. Of the 564 women identified, 319 were eligible. RESULTS: The median age at AI initiation was 65 years (range 51-85 years), and the median duration of AI therapy was 28 months (1-72 months). The median number of DEXA scans per woman was 1 (0-4), performed at a median frequency of 24 months (1-48 months). Recommendations for calcium and vitamin D were in 66 and 59% of women, respectively. There were 52 (16%) women who received antiresorptive treatments with bisphosphonates (69%), denosumab (25%), or both drugs (6%). Based on guideline recommendations from six societies, starting antiresorptive treatment was unnecessary in 15-54% of women. CONCLUSIONS: In this single health system experience, women start antiresorptive drugs that are unnecessary in 15-52%. These results highlight the nonuniformity in guideline recommendations, and this has implications for quality of care, cost-effectiveness, and value-of-care analyses for preventing fractures.
INTRODUCTION: Aromatase inhibitors (AIs) are the preferred therapy for postmenopausal women with early-stage estrogen receptor-positive breast cancers. However, their use causes bone loss and increased risks of osteoporosis and fractures. METHODS: This is a retrospective review of all postmenopausal women with breast cancer diagnosed and treated with AI between 2010 and 2015. Of the 564 women identified, 319 were eligible. RESULTS: The median age at AI initiation was 65 years (range 51-85 years), and the median duration of AI therapy was 28 months (1-72 months). The median number of DEXA scans per woman was 1 (0-4), performed at a median frequency of 24 months (1-48 months). Recommendations for calcium and vitamin D were in 66 and 59% of women, respectively. There were 52 (16%) women who received antiresorptive treatments with bisphosphonates (69%), denosumab (25%), or both drugs (6%). Based on guideline recommendations from six societies, starting antiresorptive treatment was unnecessary in 15-54% of women. CONCLUSIONS: In this single health system experience, women start antiresorptive drugs that are unnecessary in 15-52%. These results highlight the nonuniformity in guideline recommendations, and this has implications for quality of care, cost-effectiveness, and value-of-care analyses for preventing fractures.
Entities:
Keywords:
Antiresorptive drugs; Antiresorptive therapies; Aromatase inhibitors; Vitamin D
Authors: H Eidtmann; R de Boer; N Bundred; A Llombart-Cussac; N Davidson; P Neven; G von Minckwitz; J Miller; N Schenk; R Coleman Journal: Ann Oncol Date: 2010-05-05 Impact factor: 32.976
Authors: Adam M Brufsky; W Graydon Harker; J Thaddeus Beck; Linda Bosserman; Charles Vogel; Christopher Seidler; Lixian Jin; Ghulam Warsi; Eliza Argonza-Aviles; John Hohneker; Solveig G Ericson; Edith A Perez Journal: Cancer Date: 2011-10-10 Impact factor: 6.860
Authors: Sundeep Khosla; Jane A Cauley; Juliet Compston; Douglas P Kiel; Clifford Rosen; Kenneth G Saag; Elizabeth Shane Journal: J Bone Miner Res Date: 2016-12-29 Impact factor: 6.741
Authors: Fernando U Kay; Vinh Ho; Edmund B Dosunmu; Avneesh Chhabra; Keenan Brown; Xinhui Duan; Orhan K Öz Journal: Clin Nucl Med Date: 2021-01 Impact factor: 7.794
Authors: Komal Waqas; Joana Lima Ferreira; Elena Tsourdi; Jean-Jacques Body; Peyman Hadji; M C Zillikens Journal: J Bone Oncol Date: 2021-03-18 Impact factor: 4.072